Could a natural hormone help tame a common heart rhythm disorder?

NCT ID NCT07359872

Not yet recruiting Disease control Sponsor: Deeptankar DeMazumder Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests whether relaxin, a natural hormone given as a daily injection, can reduce the burden of atrial fibrillation (AF) in 208 veterans who have not responded to standard medications and are scheduled for catheter ablation. The study aims to see if relaxin can counteract harmful electrical changes in the heart caused by oxidative stress, potentially lowering AF recurrence after the procedure. It is a Phase 1/2 study, meaning it is primarily evaluating safety and early effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relaxin (a naturally occurring hormone given as a daily injection)
What this could lead to: If it works, this could point toward a new treatment to reduce atrial fibrillation recurrence after standard ablation procedures.
What could go wrong: This is an early Phase 1/2 trial with only 208 participants, so results may not apply broadly. The treatment is still experimental and may not prove effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABLATION OF ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation cardiac rhythm disease heart failure stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABLATION OF ATRIAL FIBRILLATION ARRHYTHMIA ATRIAL FIBRILLATION (AF) CATHETER ABLATION HEART FAILURE MAJOR CARDIOVASCULAR EVENT OXIDATIVE STRESS STROKE

More trials for these conditions

Other studies related to the condition(s) this trial covers.